Literature DB >> 20360150

Rehabilitation in practice: Spasticity management.

V L Stevenson1.   

Abstract

This series of articles for rehabilitation in practice aims to cover a knowledge element of the rehabilitation medicine curriculum. Nevertheless they are intended to be of interest to a multidisciplinary audience. The competency addressed in this article is 'The trainee consistently demonstrates a knowledge of the pathophysiology of various specific impairments including spasticity'. Spasticity is an extremely common feature of chronic neurological conditions and, if badly managed, it can result in pain, contractures and pressure sores, all of which can impact on function. It is therefore essential that a multidisciplinary management strategy is in place to help the individual manage their particular situation through education with timely access to interventions including instigation of a physical management programme and medication such as baclofen, tizanidine, dantrolene, benzodiazepines and gabapentin. Further treatment options for focal spasticity are botulinum toxin and phenol nerve blocks or intrathecal baclofen or phenol for predominant lower limb spasticity. Ongoing assessment with the use of appropriate outcome measures can both guide choice of treatment and monitor efficacy.

Entities:  

Mesh:

Year:  2010        PMID: 20360150     DOI: 10.1177/0269215509353254

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  17 in total

1.  The effect of extracorporeal shock wave therapy on lower limb spasticity in subacute stroke patients.

Authors:  Seung Won Moon; Jin Hoan Kim; Mi Jin Jung; Seungnam Son; Joong Hoon Lee; Heesuk Shin; Eun Shin Lee; Chul Ho Yoon; Min-Kyun Oh
Journal:  Ann Rehabil Med       Date:  2013-08-26

Review 2.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Use of injectable spasticity management agents in a cancer center.

Authors:  Jack Fu; Carolina Gutiérrez; Eduardo Bruera; Ying Guo; Shana Palla
Journal:  Support Care Cancer       Date:  2012-11-11       Impact factor: 3.603

Review 4.  Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Authors:  Uwe K Zettl; Paulus Rommer; Petra Hipp; Robert Patejdl
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

5.  Decrease of spasticity after hybrid assistive limb® training for a patient with C4 quadriplegia due to chronic SCI.

Authors:  Akira Ikumi; Shigeki Kubota; Yukiyo Shimizu; Hideki Kadone; Aiki Marushima; Tomoyuki Ueno; Hiroaki Kawamoto; Yasushi Hada; Akira Matsumura; Yoshiyuki Sankai; Masashi Yamazaki
Journal:  J Spinal Cord Med       Date:  2016-10-20       Impact factor: 1.985

6.  Treatment of spasticity in spinal cord injury with botulinum toxin.

Authors:  Ramiro Palazón-García; Mónica Alcobendas-Maestro; Ana Esclarin-de Ruz; Ana María Benavente-Valdepeñas
Journal:  J Spinal Cord Med       Date:  2018-06-05       Impact factor: 1.985

7.  Assessment of the impact of an exercise program on the physical and functional capacity in patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay: An exploratory study.

Authors:  Olivier Audet; Hung Tien Bui; Maxime Allisse; Alain-Steve Comtois; Mario Leone
Journal:  Intractable Rare Dis Res       Date:  2018-08

8.  Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury.

Authors:  A G Rabchevsky; S P Patel; H Duale; T S Lyttle; C R O'Dell; P H Kitzman
Journal:  Spinal Cord       Date:  2010-06-01       Impact factor: 2.772

9.  Physical therapy combined with corticosteroid intervention for systemic lupus erythematosus with central nervous system involvement: a case report.

Authors:  In-Hee Lee; Young Uk Ryu
Journal:  J Phys Ther Sci       Date:  2014-11-13

Review 10.  Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Authors:  Jose Eustasio Meca-Lallana; Rocío Hernández-Clares; Ester Carreón-Guarnizo
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.